UroGen Pharma Ltd (Symbol: URGN) has seen its stock price rise to $46.43 per share, surpassing the average 12-month analyst target price of $44.75. This shift occurred recently, prompting investors to reassess the company’s valuation and future potential.
Analysts have set a range of targets for URGN, with eight different analysts contributing to the average. The lowest target is $40.00 and the highest is $50.00, resulting in a standard deviation of $3.575. Currently, URGN holds seven “Strong Buy” ratings and two “Hold” ratings, reflecting a favorable sentiment among analysts.
The average analyst rating stands at 1.44 on a scale where 1 is Strong Buy and 5 is Strong Sell. These insights are based on data from Zacks Investment Research.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
